Nyrada Inc. (NYR.AX)
AUD 0.12
(-4.17%)
AUD 0.12
(-4.17%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -4.59 Million AUD | 50.29% |
| 2023 | -9.24 Million AUD | -88.25% |
| 2022 | -4.85 Million AUD | 13.29% |
| 2021 | -3.52 Million AUD | 14.32% |
| 2020 | -5.63 Million AUD | -67.59% |
| 2019 | -3.44 Million AUD | -81.1% |
| 2018 | -2.18 Million AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -2.25 Million AUD | 0.0% |
| 2024 FY | - AUD | 50.18% |
| 2024 Q2 | -2.29 Million AUD | 0.0% |
| 2023 FY | - AUD | -88.25% |
| 2023 Q2 | -3.73 Million AUD | 0.0% |
| 2023 Q4 | -5.41 Million AUD | 0.0% |
| 2022 Q4 | -2.04 Million AUD | 0.0% |
| 2022 FY | - AUD | 13.29% |
| 2022 Q2 | -2.81 Million AUD | 0.0% |
| 2021 Q4 | -2.9 Million AUD | 0.0% |
| 2021 FY | - AUD | 14.32% |
| 2021 Q2 | -2.73 Million AUD | 0.0% |
| 2020 FY | - AUD | -67.59% |
| 2020 Q4 | -4.2 Million AUD | 0.0% |
| 2020 Q2 | -2.24 Million AUD | 0.0% |
| 2019 Q2 | -2.27 Million AUD | -100.0% |
| 2019 Q4 | -1.19 Million AUD | 0.0% |
| 2019 FY | - AUD | -81.1% |
| 2019 Q1 | -1.13 Million AUD | 0.0% |
| 2018 FY | - AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | 13.323% |
| Biome Australia Limited | -1.57 Million AUD | -191.221% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 89.871% |
| Biotron Limited | -5.04 Million AUD | 8.806% |
| Acrux Limited | -7.93 Million AUD | 42.048% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 76.516% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 66.98% |
| BTC Health Limited | 1.05 Million AUD | 535.54% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | 59.325% |
| CSL Limited | 4.73 Billion AUD | 100.097% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 89.706% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 108.862% |
| Immutep Limited | -42.87 Million AUD | 89.28% |
| Memphasys Limited | -3.3 Million AUD | -38.954% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 102.307% |
| Noxopharm Limited | -5.94 Million AUD | 22.694% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 36.037% |
| Race Oncology Limited | -14.2 Million AUD | 67.64% |
| Starpharma Holdings Limited | -12.57 Million AUD | 63.455% |
| Tissue Repair Ltd | -5.77 Million AUD | 20.412% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 144.299% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -215.529% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -54.495% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 87.387% |
| Patrys Limited | -3.49 Million AUD | -31.615% |
| Orthocell Limited | -11.68 Million AUD | 60.653% |
| Imugene Limited | -147.97 Million AUD | 96.894% |
| PYC Therapeutics Limited | -38.11 Million AUD | 87.942% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | 41.727% |
| Cynata Therapeutics Limited | -9.95 Million AUD | 53.808% |
| Arovella Therapeutics Limited | -8.83 Million AUD | 47.967% |
| Nanollose Limited | -1.14 Million AUD | -300.401% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -537.971% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -155.873% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -0.803% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -63.095% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 120.013% |
| Dimerix Limited | -24.95 Million AUD | 81.585% |
| PharmAust Limited | -9.45 Million AUD | 51.372% |
| Hexima Limited | -995.54 Thousand AUD | -361.678% |
| AnteoTech Limited | -11.57 Million AUD | 60.278% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 92.878% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 78.476% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -41.748% |
| Actinogen Medical Limited | -12.92 Million AUD | 64.429% |
| Immuron Limited | -6.19 Million AUD | 25.776% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -142.212% |